BioMimetic Therapeutics, Inc. to Highlight Pre-Clinical and Clinical Activities at ORS and AAOS Meetings
FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced its schedule of events at the Orthopedic Research Society (ORS) and the American Academy of Orthopedic Surgeons (AAOS) meetings. These meetings are being held consecutively in New Orleans, LA beginning March 6, 2010.
ORS Meeting; March 6 – March 9
The following poster will be presented by BioMimetic scientists at various times during the ORS meeting from March 6 – March 9 at the Ernest Morial Convention Center Hall H:
- Poster #1172 :: Rotator Cuff Repair in an Ovine Model using a Combination Product Comprised of a Type I Bovine Collagen Matrix and rhPDGF-BB
The following poster will be presented by Dr. Lew Schon, one of BioMimetic’s U.S. clinical investigators, at various times during the ORS meeting from March 6 – March 9 at the convention center in Hall H:
- Poster #1118 :: Primary Human Tenocyte Responses to rhPDGF-BB
There will be one podium presentation during the ORS meeting featuring the use of rhPDGF-BB:
- Dr. Charlie Hee, scientist, sports medicine for BioMimetic Therapeutics, will present (Paper #220) Evaluation of rhPDGF-BB in Combination with a Flowable Collagen Matrix for the Treatment of Acute Achilles Tendon Injury. Dr. Hee’s presentation will take place on Tuesday, March 9 at1:15 CST at the convention center in room 293 – 296.
AAOS Meeting; March 10 – March 13
There will be one podium presentation during the AAOS Meeting featuring the use of rhPDGF-BB:
- Dr. Christopher DiGiovanni, BioMimetic’s lead U.S. clinical investigator, will present A PRC, Multi-Center, Pivotal Human Clinical Trial to Evaluate the Safety and Effectiveness of Augment Bone Graft as a Substitute for Autologous Bone during the AOFAS Specialty Day program. Dr. DiGiovanni’s presentation will take place on Saturday, March 13 at 7:14 a.m. CST at the Ernest Morial Convention Center in Room R09.
Additionally, BioMimetic will host a commercial exhibit booth #3633 at the convention center in Hall D between 9:00 a.m. – 5:00 p.m. CST from March 10 – March 12.
The Company will also host an investor and analyst meeting on Thursday, March 11 at 5:00 p.m. CST at the Windsor Court Hotel New Orleans in La Chinoiserie B located on the 23rdfloor. The program will highlight pre-clinical and clinical data presented at the ORS and AAOS meetings. It will also focus on clinical and market opportunities and will provide updates on the Company’s clinical pipeline. Contact BioMimetic’s corporate communications department for further information.
Investor Conference Presentation
In addition to the presentations being held at ORS and AAOS, Dr. Samuel Lynch, president and chief executive officer, will provide an update of corporate activities at the 2010 Canaccord Adams Musculoskeletal Conference. The presentation will take place at the Sheraton New Orleans Hotel on Tuesday, March 10 at 4:00 p.m. CST. A live audio webcast of the presentation will be available at http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2550240 and on the Company’s website at www.biomimetics.com. The webcast will be accessible for a period of at least 30 days.
About BioMimetic Therapeutics
BioMimetic Therapeutics is a biotechnology company utilizing purified recombinant human platelet-derived growth factor (rhPDGF-BB) in combination with tissue specific matrices as its primary technology platform for promotion of tissue healing and regeneration. rhPDGF-BB is a synthetic form of one of the body’s principal agents to stimulate and direct healing and regeneration. The mechanism of action of this platform technology suggests it may be effective in a broad array of musculoskeletal applications, including the repair of bone, ligament, tendon and cartilage. Through the commercialization of this technology, BioMimetic seeks to become the leading company in the field of orthopedic regenerative medicine. In 2005, BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration. Additionally, BioMimetic Therapeutics has completed and ongoing clinical trials with its product candidates Augment™ Bone Graft and Augment™ Injectable in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. In November 2009, BioMimetic received approval from Health Canada to begin marketing Augment as an alternative to the use of autograft in foot and ankle fusion indications in Canada. In February 2010, the Company submitted its Pre-Marketing Approval (PMA) application to the FDA for the approval of Augment Bone Graft.
GEM 21S is a trademark of Luitpold Pharmaceuticals, Inc., who now owns this dental related product and markets it through its Osteohealth Company in the United States and Canada.
For further information, visit www.biomimetics.com or contact Kearstin Patterson, corporate communications, at 615-236-4419.
